DK1401438T3 - Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer - Google Patents

Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer

Info

Publication number
DK1401438T3
DK1401438T3 DK01952097T DK01952097T DK1401438T3 DK 1401438 T3 DK1401438 T3 DK 1401438T3 DK 01952097 T DK01952097 T DK 01952097T DK 01952097 T DK01952097 T DK 01952097T DK 1401438 T3 DK1401438 T3 DK 1401438T3
Authority
DK
Denmark
Prior art keywords
cyclopamine
treatment
tumors
cell carcinoma
basal cell
Prior art date
Application number
DK01952097T
Other languages
Danish (da)
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1401438(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of DK1401438T3 publication Critical patent/DK1401438T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK01952097T 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer DK1401438T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
DK1401438T3 true DK1401438T3 (da) 2006-02-13

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01952097T DK1401438T3 (da) 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Country Status (14)

Country Link
EP (4) EP1561464A3 (es)
JP (3) JP2004536045A (es)
KR (1) KR20090125833A (es)
CN (2) CN1525859B (es)
AT (2) ATE305300T1 (es)
AU (1) AU2001272892B8 (es)
BR (1) BR0117063A (es)
CA (1) CA2452151C (es)
DE (2) DE60113733T2 (es)
DK (2) DK1401438T3 (es)
ES (3) ES2534400T3 (es)
PT (1) PT1411938E (es)
RU (1) RU2312661C2 (es)
WO (2) WO2002078703A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
DK1401438T3 (da) * 2001-07-02 2006-02-13 Sinan Tas Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
WO2007024971A2 (en) * 2005-08-22 2007-03-01 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
EP1998785A4 (en) * 2006-02-21 2009-06-17 Univ Michigan CANCER TREATMENT USING A HEDGEHOG SIGNALING PATH
NZ576467A (en) * 2006-10-31 2012-03-30 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP2010520310A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド シクロパミンラクタム類似体及びその使用方法
EP2129677B1 (en) 2007-03-07 2014-12-17 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
ES2717797T3 (es) 2007-12-27 2019-06-25 Infinity Pharmaceuticals Inc Métodos para reducción estereoselectiva de derivados de 4-en-3-ona de ciclopamina
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
US8551789B2 (en) 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CN102574791A (zh) 2009-08-05 2012-07-11 无限药品股份有限公司 环杷明类似物的酶促转氨基反应
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
EP2950885B1 (en) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2023027648A1 (en) 2021-09-13 2023-03-02 Tas Sinan Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768130B2 (en) * 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
JP2003501395A (ja) * 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
AU781524B2 (en) * 1999-10-13 2005-05-26 Johns Hopkins University School Of Medicine, The Regulators of the hedgehog pathway, compositions and uses related thereto
WO2001040438A2 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
DK1401438T3 (da) * 2001-07-02 2006-02-13 Sinan Tas Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis

Also Published As

Publication number Publication date
EP2216022A1 (en) 2010-08-11
BR0117063A (pt) 2004-07-27
RU2004103074A (ru) 2005-05-10
CN1230169C (zh) 2005-12-07
WO2002078703A1 (en) 2002-10-10
WO2002078703A8 (en) 2003-06-12
CN1525859A (zh) 2004-09-01
CA2452151C (en) 2012-01-03
JP2010132691A (ja) 2010-06-17
ES2246011T3 (es) 2006-02-01
EP2216022B1 (en) 2015-01-07
CN1522146A (zh) 2004-08-18
DE60113733D1 (de) 2006-02-09
EP1561464A3 (en) 2007-04-25
EP1401438B1 (en) 2005-09-28
AU2001272892B8 (en) 2006-05-04
JP5424923B2 (ja) 2014-02-26
DK1411938T3 (da) 2005-11-07
JP2004536045A (ja) 2004-12-02
EP2862570A1 (en) 2015-04-22
DE60204966T2 (de) 2006-05-18
EP1561464A2 (en) 2005-08-10
RU2312661C2 (ru) 2007-12-20
KR20090125833A (ko) 2009-12-07
AU2001272892B2 (en) 2006-03-16
ATE299022T1 (de) 2005-07-15
PT1411938E (pt) 2005-11-30
DE60113733T2 (de) 2006-06-29
CN1525859B (zh) 2010-05-05
ES2534400T3 (es) 2015-04-22
CA2452151A1 (en) 2002-10-10
JP2014028834A (ja) 2014-02-13
DE60204966D1 (de) 2005-08-11
WO2002078704A1 (en) 2002-10-10
ES2250434T3 (es) 2006-04-16
ATE305300T1 (de) 2005-10-15
EP1401438A1 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
DK1401438T3 (da) Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
MA26973A1 (fr) Activateurs glucokinase isoindolin-1-one
NZ544472A (en) Compounds and therapeutical use thereof
HK1040368A1 (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors andthe drug obtained thereby.
ATE408601T1 (de) Fredericamycin-derivate
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0121490D0 (en) Ciompounds
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
AR028476A1 (es) Tratamiento del cancer
MY129310A (en) C-4 carbonate taxanes
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
GB0121494D0 (en) Compounds
IS2488B (is) Fyrirbygging á krabbameini í ristli og endaþarmi
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin
DE60003189D1 (de) Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält
MD1919G2 (ro) Remediu medicamentos